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ABSTRACT
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Because 
of a high rate of immunoglobulin synthesis, the endoplasmic reticulum of MM cells 
is subjected to elevated basal levels of stress. Consequently, proteasome inhibitors, 
which exacerbate this stress by inhibiting ubiquitin-proteasome-mediated protein 
degradation, are an important new class of chemotherapeutic agents being used 
to combat this disease. However, MM cells still develop resistance to proteasome 
inhibitors such as carfilzomib. Toward this end, we have established carfilzomib-
resistant derivatives of MM cell lines. We found that resistance to carfilzomib was 
associated with elevated levels of prosurvival autophagy, and Kruppel-like factor 4 
(KLF4) was identified as a contributing factor. Expression levels as well as nuclear 
localization of KLF4 protein were elevated in MM cells with acquired carfilzomib 
resistance. Chromatin immunoprecipitations indicated that endogenous KLF4 bound 
to the promoter regions of the SQSTM1 gene encoding the ubiquitin-binding adaptor 
protein sequestosome/p62 that links the proteasomal and autophagic protein 
degradation pathways. Ectopic expression of KLF4 induced upregulation of SQSTM1. 
On the other hand, inhibitors of autophagy sensitized MM cells to carfilzomib, even 
in carfilzomib-resistant derivatives having increased expression of the multidrug 
resistance protein P-glycoprotein. Thus, we report here a novel function for KLF4, 
one of the Yamanaka reprogramming factors, as being a contributor to autophagy 
gene expression which moderates preclinical proteasome inhibitor efficacy in MM.
INTRODUCTION
Multiple myeloma (MM), the second most 
common hematologic malignancy in the United States, 
is characterized by the accumulation of clonal plasma 
cells in the bone marrow [1]. Although MM patients 
initially respond to therapy, they inevitably relapse due 
to the development of treatment resistance [2]. The 
introduction of the proteasome inhibitor bortezomib has 
improved clinical outcome of MM patients [3]. However, 
MM cells acquire resistance to bortezomib by diverse 
mechanisms [4-8]. Carfilzomib is a second generation 
proteasome inhibitor that was approved in 2012 by the 
U.S. Food and Drug Administration for the treatment 
of relapsed/refractory MM patients who have received 
at least two prior therapies including bortezomib and 
an immunomodulatory drug [9]. While encouraging, 
the overall response rates to carfilzomib monotherapy 
in pivotal phase II studies were <25% (17.1% in the 
PX‑171‑004 study and 23.7% in the PX‑171‑003‑A1 
study, respectively) [10, 11], indicating that the majority 
of the MM cells that became resistant to bortezomib also 
exhibited resistance to carfilzomib. Thus, it is important 
to elucidate the underlying mechanisms of proteasome 
inhibitor resistance in MM and identify novel agents that 
will enhance therapeutic efficacy of this class of anti-MM 
drugs.
MM exhibits considerable genetic heterogeneity, 
with particular cytogenetic abnormalities such as 
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the t(4;14) chromosomal translocation consistently 
associated with poor outcome [12]. In previous work, we 
identified upregulated expression of the ABCB1‑encoded 
P-glycoprotein multidrug resistance efflux pump in 
t(4;14)‑positive KMS‑34 MM cells following short‑term 
exposure to carfilzomib [13]. To gain further insight into 
the various mechanisms of carfilzomib resistance, we 
subjected another t(4;14)‑positive MM cell line, KMS‑
11, together with KMS‑34 to long‑term selection in 
increasingly higher concentrations of the drug, deriving 
carfilzomib-resistant KMS-11/Cfz and KMS-34/Cfz cells, 
respectively. Of note, overexpression of ABCB1 was 
not observed in KMS‑11/Cfz cells. Gene set enrichment 
analysis (GSEA) [14] of microarray gene expression 
profiling data implicated increased expression of the 
pluripotency reprogramming factor Kruppel‑like factor 4 
(KLF4) [15] as contributing to carfilzomib resistance in 
both cases. 
Depending on the type of cancer and genetic context, 
KLF4 can act as either a tumor suppressor or an oncogene 
[16]. Notably, high levels of KLF4 expression often occur 
in MM patients carrying the t(4;14) translocation [17, 
18]. Moreover, it was previously reported that exogenous 
expression of KLF4 partially protected some MM cell 
lines from cytotoxicity induced by the alkylating agent 
melphalan, and the partial protection was attributed to a 
proliferation block [19]. In the current study, we found 
that acquisition of carfilzomib resistance in both t(4;14)‑
positive MM cell line models was associated with reduced 
cell proliferation, decreased plasma cell maturation, and 
activation of prosurvival autophagy. Specifically, we show 
that KLF4 plays a role in prosurvival autophagy by binding 
to the promoter regions and increasing the expression of 
SQSTM1 encoding the ubiquitin‑binding adaptor protein 
sequestosome (SQSTM1/p62) that links the proteasomal 
and selective autophagic protein degradation pathways 
[20, 21]. Furthermore, resensitization of KMS‑11/Cfz and 
KMS-34/Cfz cells to carfilzomib could be achieved by 
cotreatment with the autophagy inhibitor chloroquine [22].
RESULTS
KLF4 contributes to molecular phenotype of 
carfilzomib-resistant MM cells
KMS‑11 and KMS‑34 cells were exposed to 
stepwise increasing concentrations of carfilzomib over 
a period of 18 weeks: cells adapted to growth in 4 nM 
carfilzomib by 4 weeks, in 6 nM in another 6 weeks and in 
12 nM after a further 8 weeks, albeit proliferating slower 
than parental cells not exposed to the drug. The resulting 
MM cell cultures, denoted KMS‑11/Cfz and KMS‑34/
Cfz, respectively, retained resistance to carfilzomib 
even when tested after removal of selective pressure for 
approximately 8 weeks. In the current study, KMS‑11/Cfz 
and KMS-34/Cfz cells were profiled for gene expression 
after 1 week of growth in the absence of carfilzomib 
together with parental KMS‑11 and KMS‑34 cells which 
had not been selected in the drug.
We employed GSEA to query gene sets in the 
Molecular Signature Database (MSigDB) to uncover 
processes or pathways shared between KMS‑11/Cfz 
and KMS‑34/Cfz cells that potentially contributed to 
carfilzomib resistance [14]. We first applied GSEA to 
examine gene sets from the canonical pathways (C2:CP) 
collection of MSigDB (1,330 gene sets). The most 
significantly enriched set of upregulated genes in the 
carfilzomib-resistant derivatives was the proteasome 
pathway (Kegg: hsa03050), with PSMB5 encoding the 
β5 proteasome subunit targeted by carfilzomib as the top-
ranked gene (normalized enrichment score, NES = 2.62, 
false discovery rate, FDR < 0.001; Figure S1A) [23]. The 
strength of the GSEA method is its utility in identifying 
modest changes in expression of groups of genes 
distributed across entire networks or pathways [14]. Real‑
time reverse transcription polymerase chain reaction (qRT‑
PCR) analysis validated the microarray expression data 
that PSMB5 mRNA levels were only slightly increased 
(Table 1). Likewise, no marked increase was observed 
in mRNA for the immunoproteasome β5i/LMP7 subunit 
(encoded by PSMB8) that is also specifically targeted by 
carfilzomib [23]. Based on prior findings that bortezomib-
resistant cell lines with 2‑ to 4‑fold increased PSMB5 
mRNA levels retained sensitivity to carfilzomib [24], 
these results suggested that additional mechanisms may 
contribute to carfilzomib resistance in KMS-11/Cfz and 
KMS‑34/Cfz cells.
It was recently demonstrated that MM cells can 
acquire resistance to bortezomib via de‑commitment to 
plasma cell differentiation [7]. Notably, among 1,910 gene 
sets in the immunologic signatures (C7) collection, three 
of those that were highly scored reflected a partial reversal 
of plasma cell maturation in the carfilzomib-resistant MM 
derivatives. The most significantly enriched gene set in 
KMS‑11/Cfz and KMS‑34/Cfz cells corresponded to 
genes with increased expression in IgM‑memory B cells 
versus plasma cells (NES = 1.75, FDR = 0.005; Figure 
1A). A set containing genes more highly expressed in 
naive B cells than in plasma cells (NES = 1.49, FDR = 
0.06; Figure 1B) and one containing genes with higher 
levels of expression in Ig isotype‑switched memory B 
cells relative to plasma cells (NES = 1.46, FDR = 0.06; 
Figure 1C) were also significantly enriched. We observed 
that KLF4 was included within the leading edge subset 
of upregulated genes in all three gene sets, in line with 
its higher expression in naive and memory B cells than 
in plasma cells [25‑27]. Furthermore, using GeneSpring 
analysis software, we found overrepresentation of KLF4 
target genes previously characterized by genome‑wide 
chromatin immunoprecipitation (ChIP) in embryonic stem 
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cells by Orkin and colleagues [28] among the differentially 
expressed genes in KMS‑11/Cfz (89 out of 887 genes, fold 
change, FC ≥ 1.4; P = 2.02 x 10‑3) and KMS‑34/Cfz (92 
out of 888 genes, FC ≥ 1.5; P = 6.47 x 10‑4) (Table S1), 
suggesting that upregulation of KLF4 may contribute to 
carfilzomib resistance.
We confirmed increased expression of KLF4 
mRNA in carfilzomib-resistant MM cells by qRT-
Table 1: Gene expression changes associated with acquisition of 
carfilzomib resistance (KMS-11/Cfz and KMS-34/Cfz) and KLF4 
overexpression (KMS-11/KLF4) in MM cells
Gene Fold Change
KMS-11/Cfz KMS-34/Cfz KMS-11/KLF4
CCND1 0.06 0.17 1.12
CYP1A1 3.02 2.77 2.17
GLIPR1 1.19 1.22 0.70
HGF 0.76 0.45 0.65
HOXB7 1.33 1.69 1.38
ID1 3.61 2.29 1.63
IFIT3 1.25 1.87 0.73
IGF1 0.69 0.93 1.07
MAPT 1.21 0.94 1.13
NQO1 1.85 1.25 1.21
NQO2 1.09 1.05 0.75
P4HA2 0.70 0.67 0.68
PSMB5 1.09 1.11 0.83
SLAMF7 0.12 0.53 0.59
TLR4 1.43 3.56 1.13
Shown are fold changes relative to corresponding parental cells (mean 
values of three qRT‑PCR experiments).
Figure 1: GSEA enrichment plots and heat maps of differentially expressed B lineage-related genes associated with 
acquisition of carfilzomib resistance in KMS-11 and KMS-34 cells. A. Gene set: GSE13411_IGM_MEMORY_BCELL_VS_
PLASMA_CELL_UP (M3249). B. Gene set: GSE13411_NAIVE_BCELL_VS_PLASMA_CELL_UP (M3243). C. Gene set: GSE13411_
SWITCHED_MEMORY_BCELL_VS_PLASMA_CELL_UP (M3251). FDR, false discovery rate; NES, normalized enrichment score; 
CfzR, carfilzomib-resistant derivatives; KLF4 is indicated.
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PCR analysis (Figure 2A), which was paralleled by a 
corresponding increase in KLF4 protein levels (~3.0 
± 0.7‑fold, n = 4, P < 0.009 by paired Student’s t test) 
detected by western blotting (Figure 2B). Consistent with 
its function as a transcriptional regulator and potential 
role in the carfilzomib-resistant phenotype [29, 30], 
immunofluorescence confocal microscopy revealed more 
prominent nuclear localization of KLF4 in the carfilzomib-
resistant MM derivatives (Figure 2C).
We tested the hypothesis that KLF4 might contribute 
to the molecular phenotype of carfilzomib-resistant 
MM cells by short‑term expression of a KLF4 cDNA in 
KMS‑11 cells (denoted KMS‑11/KLF4). Fourteen genes 
showing differential expression in KMS‑11/Cfz (FC 
≥ 1.4) and/or KMS-34/Cfz (FC ≥ 1.5) versus parental 
MM cells were selected, and their expression levels 
compared to those in KMS‑11/KLF4 cells by qRT‑PCR 
analysis (Table 1). A substantial degree of correlation 
was found between the expression changes associated 
with the introduction of exogenous KLF4 and acquisition 
of carfilzomib resistance in KMS-11/Cfz (r = 0.77) and 
KMS‑34/Cfz cells (r = 0.59) for the selected set of genes 
(Table 1). Of note, several of the genes that exhibited 
KLF4‑induced changes in expression — CYP1A1, 
NQO1, HOXB7 and ID1 — were previously identified as 
direct KLF4 targets by genome‑wide ChIP analysis [28]. 
Another of the genes, SLAMF7 encodes CD319, a cell 
surface marker specifically upregulated at the plasma cell 
stage during B cell differentiation [27, 31]. We verified 
that SLAMF7 mRNA levels were downregulated in the 
carfilzomib-resistant MM derivatives in accord with 
the less differentiated plasma cell phenotype revealed 
by GSEA analysis above. Moreover, SLAMF7 mRNA 
levels were also reduced following ectopic expression 
of KLF4 in KMS‑11 cells. Together, the accumulated 
data supported the notion that carfilzomib-resistant MM 
cells had increased KLF4 transcriptional activity which 
was associated with the partial reversal of plasma cell 
maturation during acquisition of drug resistance. 
GSEA identifies altered expression of KLF4 target 
genes associated with autophagy and metabolic 
pathways in carfilzomib-resistant MM cells
We next used GSEA to examine gene sets from 
the C2:CGP chemical and genetic perturbations (3,395 
gene sets) and C6 oncogenic signatures (189 gene sets) 
collections of MSigDB. A highly enriched C2:CGP gene 
set in KMS‑11/Cfz and KMS‑34/Cfz cells (NES = 2.02, 
FDR < 0.007; Figure 3A) represented molecular targets 
that were upregulated during inhibition of MM cell growth 
following treatment with adaphostin [32]. Bortezomib 
reportedly triggered similar effects, and a recent study 
identifying c‑Abl as a regulator of proteasome homeostasis 
provides some insight into the cross‑talk between the 
pathways involved [33]. Interestingly, included in the 
leading edge subset were several genes associated with 
autophagy (highlighted in Figure 3). Among them were 
MAP1LC3B encoding the autophagic effector protein 
microtubule-associated protein 1 light chain Cβ, and 
SQSTM1 encoding the selective autophagy receptor 
Figure 2: KLF4 expression in KMS-11 and carfilzomib-resistant KMS-11/Cfz cells. A. Relative KLF4 mRNA levels as 
determined by qRT‑PCR. Also shown are KLF4 mRNA levels in KMS‑34 and KMS‑34/Cfz cells relative to KLF4 mRNA levels in KMS‑11 
cells. B. KLF4 protein levels were detected by western blotting with rabbit anti‑KLF4 monoclonal antibodies against the carboxyl terminus 
(D1F2; Cell Signaling). Representative of four experiments. KLF4 signal in KMS‑11 parental cells is less than in KMS‑11/Cfz (P < 0.009). 
C. Cells were labeled with anti-KLF4 (Alexa Fluor 568, red) or anti-eIF4E (Alexa Fluor 488, green) antibodies, and immunofluorescence 
staining was analyzed by confocal laser scanning microscopy.
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sequestosome 1/p62 [34, 35]. During autophagy, a soluble 
form of LC3B (LC3B‑I) is converted to a form (LC3B‑
II) that specifically associates with autophagosomes 
and is recognized by SQSTM1/p62 [36]. Also included 
was GADD45A, a growth arrest and DNA repair gene 
previously shown to be a KLF4‑inducible gene in 
Hodgkin lymphoma cells and a stimulator of autophagy 
during skeletal muscle atrophy [37, 38]. Moreover, the 
most highly enriched gene set in the C6 collection (NES = 
1.70, FDR = 0.05) corresponded to genes in MCF‑7 breast 
cancer cells adapted for estrogen‑independent growth in 
culture that were upregulated in the carfilzomib-resistant 
MM cells; KLF4 and GADD45A were included in the 
leading edge subset (Figure 3B). A further association 
with autophagy‑related processes was suggested by a 
recent study reporting that one of the genes in the leading 
edge subset, LAMP3 encoding lysosome‑associated 
membrane protein 3, is involved in resistance to the anti‑
estrogen tamoxifen in breast cancer cells by promoting 
prosurvival autophagy [39]. Another gene, ISG15, 
encoding an ubiquitin‑like protein, was recently shown 
to interact with SQSTM1/p62, augmenting association 
with LC3B‑II and facilitating autophagic degradation of 
aggresomes, in response to various types of cellular stress 
including proteasome inhibition [40]. Considered together, 
the genes represented in the leading edge subsets of the 
gene sets presented in Figure 3A, 3B suggested potential 
upregulation of autophagy pathways in the carfilzomib-
resistant MM derivatives.
Conversely, among the downregulated sets of 
genes that were enriched in KMS‑11/Cfz and KMS‑34/
Cfz cells, one of the most highly scored in the C2:CGP 
collection corresponded to genes belonging to an IRF4 
regulatory network that are expressed at higher levels 
during B cell differentiation (NES = ‑1.98, FDR = 
0.01; Figure 3C) [41]. SLAMF7 was included in the 
leading edge subset of downregulated genes. We noted 
that many of the other downregulated genes in the 
leading edge subset are involved in lipid metabolism 
(e.g., INSIG1, HMGCR, SCD, PAM, LDLR, SQLE, 
CYP51A1, MVK), and complementary analysis of the 
C2:CP canonical pathways collection (1,330 gene sets) 
by GSEA indicated downregulation of genes involved in 
cholesterol biosynthesis (Reactome: REACT_9405.3) in 
the carfilzomib-resistant MM cells as being statistically 
significant (NES = -2.41, FDR = 0.001; Figure S1B). 
Consistent with the inverse correlation observed between 
KLF4 levels and expression levels of these genes, several 
were previously demonstrated to be negatively regulated 
by ectopic KLF4 expression [42]. Examples included 
three genes involved in cholesterol biosynthesis: HMGCR 
encoding HMG‑CoA reductase and MVK encoding 
mevalonate kinase, early enzymes in the mevalonate 
pathway; and CYP51A1 encoding a cytochrome P450 
family member involved in the conversion of lanosterol 
to cholesterol. Additionally, although no significant 
Figure 3: GSEA enrichment plots and heat maps of gene expression changes in sets of genes coregulated in response 
to chemical and genetic perturbations associated with acquisition of carfilzomib resistance in KMS-11 and KMS-34 
cells. A. Gene set: SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE (M11189). B. Gene set: PODAR_RESPONSE_
TO_ADAPHOSTIN_UP (M16336). C. Gene set: LTE2_UP.V1_DN (M2721). Abbreviations are as in Figure 1. Selected autophagy‑related 
genes are indicated with a red asterisk. KLF4‑repressed genes are indicated with a blue asterisk. 
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enrichment of glycolysis‑related gene sets was revealed 
by GSEA, LDHA, which encodes a subunit of lactate 
dehydrogenase, a key enzyme in the glycolytic phenotype 
of cancer cells (known as the Warburg effect) [43] 
previously identified as a KLF4-repressed gene [44] 
was downregulated in the carfilzomib-resistant MM 
derivatives (Figure 3C). In view of increasing evidence 
that enhanced lipid catabolism and low glycolytic activity 
in slowly proliferating tumor cells is associated with 
autophagy induction and treatment resistance [45], the 
above observations raised the possibility that activation 
of prosurvival autophagy could be a mechanism adopted 
by the carfilzomib-resistant MM cells to counteract the 
deficiency of proteasome function and metabolic stress 
induced by carfilzomib treatment. 
Carfilzomib resistance is associated with 
prosurvival autophagy in MM cells
We first examined whether autophagic activity was 
increased in carfilzomib-resistant KMS-11/Cfz and KMS-
34/Cfz cells by flow cytometry using the fluorescent dye 
Cyto‑ID Green [46, 47]. Fluorescence signals reflect 
steady state levels of autophagosomes as a result of two 
offsetting processes: formation of autophagosomes and 
dissolution of autophagosomes upon lysosomal fusion. 
We found higher steady state levels of autophagosomes 
in resistant cells versus their parental counterparts in both 
MM cell line models (relative increase in autophagic 
activity based on Cyto-ID mean fluorescence intensity 
values = 16.6 ± 1.3, P < 0.05, paired Student’s t test; see 
Materials and Methods for details) (Figure 4A). 
Second, we investigated autophagic flux by 
measuring the processing of LC3B, an ubiquitin‑like 
protein that is converted during autophagy to a lipidated 
form (LC3B‑II) associated with autophagosome 
membranes [34]. To distinguish between synthesis, 
modification and degradation rates of LC3B, the ratio 
of the LC3B‑II faster migrating form to the nonlipidated 
precursor (LC3B‑I) is determined in the absence or 
presence of inhibitors of lysosome‑mediated proteolysis 
[48]. Both carfilzomib-resistant MM derivatives exhibited 
higher levels of synthesis and modification of LC3B (as 
measured by LC3B‑II/LC3B‑I ratio) in comparison to 
parental cells in the presence of a mixture of the lysosomal 
protease inhibitors E64d, pepstatin A and leupeptin (Figure 
4B). Increased levels of the ubiquitin cargo receptor and 
autophagy substrate SQSTM1/p62 in KMS‑11/Cfz cells in 
the presence of the lysosomal protease inhibitors was also 
consistent with more active autophagy (Figure 4C). 
Next, since SQSTM1/p62 is recruited into 
autophagosomes by lipidated LC3B‑II [49], we assessed 
the subcellular localization of LC3B and SQSTM1/p62 
proteins by immunofluorescence confocal microscopy. 
In both KMS‑11 and KMS‑34 cell line models increased 
colocalization of the two factors correlated with 
acquisition of carfilzomib resistance (P < 0.003; Figure 
4D). To further characterize autophagic activity, we used 
the fluorescent autophagosome-specific reporter construct 
encoding a GFP‑LC3 fusion protein [50], and examined 
GFP-LC3 signals by fluorescence confocal microscopy in 
KMS‑11 and KMS‑11/Cfz cells treated with or without 
carfilzomib. An increased number of GFP-LC3-II puncta 
was observed in KMS‑11/Cfz cells (Figure 5A). To 
determine whether this was associated with increased 
autophagic flux, cells were treated with carfilzomib in 
the presence of lysosomal protease inhibitors and the 
levels of endogenous LC3B‑I and LC3B‑II measured by 
western blotting. As shown in Figure 5B, the degree of 
LC3B-II stabilization as reflected by the relative increase 
in the LC3B-II/LC3B-I ratio was greater in carfilzomib-
resistant versus parental MM cells (P < 0.0001). Similar 
results were obtained when the cells were cotreated 
with chloroquine which, by increasing lysosomal pH, 
inhibits autophagic protein degradation and blocks 
autophagosome‑lysosome fusion (Figure 5B) [51]. 
The above results are consistent with the view 
that increased autophagic flux was occurring in the 
carfilzomib-resistant MM cells. Inhibition of autophagy by 
chloroquine treatment was previously reported to enhance 
carfilzomib-induced cell death of head and neck squamous 
cell carcinoma cell lines [52]. To test whether concomitant 
inhibition of autophagy would sensitize KMS‑11/Cfz and 
KMS-34/Cfz to carfilzomib, the cells were treated with 
carfilzomib in the presence or absence of chloroquine, 
and cell growth was measured by alamarBlue assay. 
Importantly, cotreatment with chloroquine diminished 
carfilzomib resistance in both KMS-11/Cfz and KMS-
34/Cfz cell lines, indicating that prosurvival autophagy 
contributes to acquired drug resistance in these MM cell 
line models (Figure 5C). 
KLF4 regulates the autophagy receptor gene 
SQSTM1
The SQSTM1/p62 protein is of particular interest 
given its role as an adaptor for both proteasomal and 
autophagic degradation of ubiquitinated proteins [20, 
21]. As shown in Figure 6A, we confirmed that SQSTM1 
mRNA levels were higher in the carfilzomib-resistant MM 
derivatives and we demonstrated that the levels increased 
upon ectopic expression of KLF4 in KMS‑11 cells by 
qRT‑PCR analysis. A review of the literature revealed that 
SQSTM1 was included in a list of direct KLF4 binding 
targets detected by genome‑wide ChIP analysis [53]. 
We therefore analyzed the genomic regions upstream 
of the SQSTM1 transcription start sites, and identified 
evolutionally conserved KLF4‑binding motifs (Figure 6B; 
Figure S2). We performed qPCR‑based ChIP analysis in 
KMS-11 and KMS-11/Cfz cells and confirmed binding to 
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Figure 4: Autophagy is induced in carfilzomib-resistant KMS-11/Cfz and KMS-34/Cfz cells. A. Fluorescence histograms 
of cells stained with the Cyto‑ID Green autophagy detection reagent. Representative examples of three independent experiments are shown 
(P < 0.05, paired Student’s t test). B., C. To assess complete autophagic flux, cells were treated overnight with or without the lysosomal 
protease inhibitors E64d (10 µg/ml), pepstatin A (PA; 10 µg/ml), and leupeptin (Leu; 1 µg/ml) [52]. Cell lysates were probed with anti‑
LC3B B. or anti‑SQSTM1 C.. D. Cells were labeled with anti‑LC3B (Alexa Fluor 568, red) or anti‑SQSTM1 (Alexa Fluor 488, green) 
antibodies, and immunofluorescence staining was analyzed by confocal laser scanning microscopy. Increased colocalization of the two 
factors in KMS-11/Cfz versus parental KMS-11 cells (yellow signals) correlated with acquisition of carfilzomib resistance (P < 0.003).
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these regions by endogenous KLF4 (Figure 6C). In these 
experiments, the KLF4 promoter region was included 
as a positive control [55], whereas GATA6 genomic 
regions were used as negative controls [28, 53]. These 
observations support the proposal that KLF4 contributes 
to carfilzomib resistance by upregulating SQSTM1 
Figure 5: Prosurvival autophagy induction in carfilzomib-resistant MM cells is antagonized by lysosomal inhibitors and 
chloroquine. A. Increased GFP-LC3 puncta formation in KMS-11/Cfz versus parental KMS-11 cells treated overnight with carfilzomib 
(50 nM). B. Increased stabilization of LC3B‑II in KMS‑11/Cfz versus parental KMS‑11 cells upon autophagy inhibition. Representative 
western blot of LC3B levels of four independent experiments is shown (P < 0.0001). Cells were treated overnight with carfilzomib (50 nM) 
in the presence or absence of the lysosomal protease inhibitors E64d (10 µg/ml), pepstatin A (PA; 10 µg/ml), and leupeptin (Leu; 1 µg/
ml) or chloroquine (10 µM). Densitometry was used to calculate the LC3B‑II/LC3B‑I ratios and the relative increases in the ratios upon 
autophagy inhibition with respect to carfilzomib only-treated controls are indicated in the graph on the right. C. Cells were treated with the 
indicated concentrations of carfilzomib for 72 hours in the presence or absence of chloroquine (10 µM). Cell viability was determined by 
alamarBlue assay. The data are presented as the mean ± S.D of three experiments. IC50 values were calculated by linear regression of the 
plots in the absence or presence of chloroquine: KMS‑11/Cfz, 35 nM versus 22 nM; KMS‑11, 12 nM versus 12 nM; KMS‑34/Cfz, 35 nM 
versus 6 nM; KMS‑34, 6 nM versus 6 nM. 
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expression in these MM cell line models.
To further investigate the potential relevance of 
a KLF4‑associated autophagy component in MM, we 
identified KLF4 profile neighbors across 304 MM patient 
samples in the Multiple Myeloma Research Consortium 
reference collection dataset (GEO accession number 
GSE26760). In agreement with earlier work [17, 18], 
the two genes dysregulated by the t(4;14) translocation, 
WHSC1 and FGFR3 [56], were among the top KLF4 
neighbors (1,470 out of 54,675 total on the array). 
Moreover, the set was enriched for genes associated 
with the annotation term “autophagy” in the NCBI Gene 
database (P = 2.34 x 10‑4). Importantly, the list included 
SQSTM1 (Table S2). These results, demonstrating 
similarity in expression pattern and shared function [57], 
suggest that contribution to prosurvival autophagy is a 
clinically relevant aspect of KLF4 expression as regards 
MM pathobiology.
Elevated expression of KLF4 and SQSTM1 is 
prognostic of poor survival in a subgroup of 
WHSC1-positive MM patients
Shaughnessy and colleagues defined a high-risk 
subgroup of MM patients by gene expression profiling 
(designated PR) based on expression of certain cell 
cycle and proliferation‑associated genes [58]. The PR 
subgroup signature was present in approximately 18% 
of newly diagnosed MM and increased during disease 
progression to 45% of relapsed cases; strikingly, many 
of the WHSC1-defined t(4;14)-positive samples were 
found to cluster in this subgroup [58]. We used the 
recently published PROGgeneV2 prognostic biomarker 
identification tool [59] to study the implications of 
WHSC1, KLF4 and SQSTM1 gene expression on 
overall survival of 47 MM patients in the PR subgroup 
(GEO accession number GSE2658). Using median gene 
expression values as bifurcation points, Cox proportional 
hazards analyses showed that elevated expression of 
these genes was associated with inferior 3‑year survival 
outcomes (Figure 7). Kaplan‑Meier plots indicated 
significant segregation in survival outcomes for patients 
with high versus low WHSC1 expression (hazard ratio, 
HR = 1.95; 95% confidence interval/CI, 1.16-3.28; P = 
0.01), with increasingly worse prognosis when high level 
coexpression of KLF4 (HR = 4.33; 95% CI, 2.04‑9.18; P 
= 1.0 x 10‑4) (Figure 7B), and KLF4 plus SQSTM1 (HR = 
8.40; 95% CI, 2.80‑25.17; P = 1.0 x 10‑4) (Figure 7C) were 
also considered. When high levels of coexpression of the 
autophagy‑associated genes MAP1LC3B and GADD45A 
Figure 6: SQSTM1 is a direct target of KLF4 upregulated in carfilzomib-resistant KMS-11/Cfz and KMS-34/Cfz cells. 
A. Expression of SQSTM1 determined by qRT‑PCR. KMS‑11/KLF4, KMS‑11 cells expressing a KLF4 cDNA. KMS‑11/M11, KMS‑11 
cells transfected with a control vector. B. Evolutionarily conserved KLF4‑binding motifs in the SQSTM1 promoter regions upstream of 
the NM_001142298 and NM_001142299 transcription start sites (Figure S2; see also Table S3 of Zaret and colleagues [54]). C. Increased 
binding of KLF4 to the SQSTM1 promoter regions indicated in B. in KMS‑11/Cfz versus parental KMS‑11 cells as determined by ChIP‑
qPCR.
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Figure 7: Prognostic value of WHSC1, KLF4 and SQSTM1 expression in MM patient survival outcomes. Kaplan‑Meier 
survival plots of 47 MM patients in a high‑risk subgroup associated with refractory/relapsed disease (GEO accession number GSE2658) 
created using PROGgeneV2. A. WHSC1 expression. B. Coexpression of WHSC1 and KLF4. C. Coexpression of WHSC1, KLF4 and 
SQSTM1. D. Coexpression of WHSC1, KLF4, SQSTM1, MAP1LC3B, and SQSTM1. E. Ratio of KLF4 to HMGCR expression. F. Ratio 
of KLF4 to LDHA expression. Median gene expression values were used as bifurcation points. HR, hazard ratio determined by Cox 
proportional hazards model.
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were also taken into account, significantly inferior overall 
survival outcomes were observed (HR = 51.21; 95% 
CI, 7.36‑356.61; P = 1.0 x 10‑4) (Figure 7D). Moreover, 
reduced tumor cell metabolism (e.g., as exemplified by 
low HMGCR or LDHA expression) was also associated 
with adverse outcomes, with high expression ratios of 
KLF4 to HMGCR (HR = 3.47; 95% CI, 1.61‑7.48; P = 
0.02) (Figure 7E) and KLF4 to LDHA (HR = 3.74; 95% 
CI, 1.66‑8.43; P = 0.001) (Figure 7F) prognostic of poor 
3‑year survival rates. 
DISCUSSION
The molecular mechanisms associated with 
the development of clinical resistance to proteasome 
inhibitors remain to be fully elucidated [4‑8]. Toward 
this end, we have endeavored to establish clinically‑
relevant carfilzomib-resistant MM cell lines [60]. In a 
previously published study, we found that upregulation 
of the ABCB1-encoded multidrug resistance efflux 
transporter P‑glycoprotein contributed to increased 
carfilzomib resistance in KMS-34 MM cells cultured 
in low concentrations (6 nM) of the drug [13]. Notably, 
our analysis of microarray data acquired for a MM 
patient treated with carfilzomib revealed increased 
ABCB1 expression during disease progression [61], 
suggesting that the mechanism could be relevant to 
carfilzomib resistance observed in the clinic [62]. To 
further elaborate mechanisms of carfilzomib resistance 
in MM, we adapted KMS‑34/Cfz to growth in 12 nM 
carfilzomib and likewise established KMS-11/Cfz 
cells resistant to 12 nM carfilzomib by exposure to 
stepwise increasing concentrations of the drug. Unlike 
KMS‑34/Cfz, KMS‑11/Cfz did not exhibit increased 
expression of ABCB1. Instead, we found that a common 
mechanism of carfilzomib resistance was elevated levels 
of prosurvival autophagy, and that the pluripotency‑
associated transcription factor KLF4 [15] contributed 
to the carfilzomib-resistant phenotype. Our findings are 
in accord with those of two publications that appeared 
during revision of this manuscript reporting that KLF4 
participates in autophagic pathways activated during stress 
responses in other settings [63, 64]. 
Substrates destined for selective autophagic 
destruction are recognized by receptor proteins which 
anchor the material to the expanding phagophore 
membrane via co‑binding to lipidated LC3B‑II [35, 36]. 
In recent years, the ubiquitin‑proteasome and autophagy‑
lysosome systems, once considered independent processes 
for protein degradation, are now regarded as being 
interconnected. Impairment of either pathway has been 
reported to impact the other. Ubiquitination of proteins 
targeted for destruction serves as the mechanism of 
crosstalk and ubiquitin‑binding cargo protein SQSTM1/
p62 is a critical link [20, 21]. By upregulating SQSTM1/
p62 levels in carfilzomib-resistant MM cells, KLF4 
is postulated to contribute to prosurvival autophagy 
by facilitating delivery of aggregated substrates to 
autophagosomes via LC3B‑II for subsequent destruction 
[65]. The relevance of this process in the MM therapeutic 
response to proteasome inhibition is supported by the 
recent finding that short hairpin RNA knockdown of 
SQSTM1 mRNA resulted in failure of autophagosomes 
to trap ubiquitinated cargo in MM cells, converting 
prosurvival autophagy to apoptosis [66].
KLF4 expression is consistently associated with 
MM patients carrying the t(4;14) translocation [17, 18]. 
Two genes are aberrantly expressed as a consequence 
of the translocation: WHSC1, encoding a histone 
methyltransferase (also referred to as MMSET or NSD2), 
and FGFR3 encoding a transmembrane tyrosine kinase 
[56]. Gain‑ and loss‑of function studies in MM cell lines 
have demonstrated that WHSC1 histone methyltransferase 
activity is involved in the epigenetic upregulation of KLF4 
[67, 68]. Notably, there is highly significant overlap (P 
< 1 x 10‑33) between the WHSC1 target genes identified 
and the differentially expressed genes in KMS‑11/Cfz 
(86 out of 887; FC ≥ 1.4) and KMS-34/Cfz (69 out of 
888 genes, FC ≥ 1.5). Therefore, inhibition of WHSC1 
enzymatic function or its ability to interact with chromatin 
may represent a promising future combination therapy for 
this subgroup of MM patients [67, 68].
Although the upstream pathways remain undefined, 
it is worth noting that induction of KLF4 transcription 
was previously observed in endothelial cells treated with 
bortezomib or epoxomicin (the natural epoxyketone from 
which carfilzomib was derived) [69]. Increased levels 
of KLF4 have also been observed following inhibition 
of translation by depletion of the translation initiation 
factor eIF4GI [70]. As eIF4GI depletion was reported to 
phenocopy mTOR inhibition and promote autophagy [70], 
and inhibition of mTOR activity by rapamycin induced 
KLF4 expression in other cells [71], mechanisms linking 
protein turnover and protein synthesis are implicated in 
KLF4 upregulation in the context of acquired proteasome 
inhibitor resistance [72]. 
Overexpression of KLF4 in MM cells was 
previously reported to result in cell cycle arrest [19]. We 
also observed that very high levels of exogenous KLF4 
expression reduced proliferation rates in KMS‑11 and 
KMS‑34 cells, with diminished transgene expression in 
cell populations that exhibited a growth advantage after 
1 month of culture (Figure S3). In this regard, KLF4 has 
been reported to exert growth suppressive effects in B‑cell 
non‑Hodgkin lymphoma [37], yet a recent study found 
that high nuclear expression of KLF4 in Burkitt pediatric 
lymphoma was indicative of inferior overall survival 
[73]. Thus, as in other systems [16], KLF4 regulation of 
B cell proliferation is complex and likely dependent on 
multiple factors. Along these lines, KLF4 was originally 
characterized as an epithelial oncogene by Rupert’s group 
imparting a slow growth phenotype to the transformed 
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cells [74]. In follow‑up studies of breast cancer cases, 
these investigators found that small primary tumors having 
preferential nuclear localization of KLF4 correlated with 
an increased risk of death [30]. The relative proliferative 
activity of WHSC1‑positive KLF4‑expressing MM cells 
with respect to other MM samples in the PR subgroup 
defined by Shaughnessy and colleagues [58] is not 
known. However, the fact that the hazard ratio increased 
significantly for these MM patients upon consideration of 
autophagy‑associated gene expression levels (Figure 7D), 
implicates activation of autophagy as a contributing factor 
to relapsed/refractory disease. 
Beyond its function as a direct cell cycle regulator, 
KLF4 exerts inhibitory effects on metabolic pathways 
and macromolecular synthesis [75], which include 
repression of genes encoding key enzymes involved in 
glycolysis and cholesterol biosynthesis (i.e., HMGCR, 
HMGCS1, MVK, LDHA) [42, 44]. Recent studies have 
shown that autophagy plays important roles in glucose 
homeostasis and lipid metabolism [76, 77], and the 
inverse relationship between autophagy and cell growth 
is becoming increasingly appreciated [78]. Although the 
KLF4 metabolic target genes in Figure 3C, including 
HMGCR and LDHA were only modestly downregulated 
upon acquisition of carfilzomib resistance, inhibition of 
HMGCR or LDHA enzymatic activity has resulted in 
autophagy induction in cancer cells [79, 80]. Furthermore, 
high gene expression ratios of KLF4 to HMGCR and 
KLF4 to LDHA were associated with adverse outcomes of 
certain MM patients (Figure 7E, 7F). Collectively, these 
results may raise a cautionary note regarding potential 
anti‑MM therapeutic strategies that target these metabolic 
enzymes [81, 82].
KLF4 levels decrease during B cell activation 
and differentiation into plasma cells [25‑27]. Increased 
expression of KLF4 in the carfilzomib-resistant 
KMS‑11/Cfz and KMS‑34/Cfz cells was indicative 
of “dedifferentiation” to an earlier maturation stage 
(Figure 1). Negative regulation of SLAMF7 encoding 
plasma cell-specific CD319 [27, 31] by ectopic KLF4 
expression in KMS‑11 cells (Table 1) suggests a potential 
role in the process. That this MM cell line phenomenon 
is biologically relevant is supported by work from 
Yaccoby who first described the ability of primary MM 
cells to dedifferentiate into an immature plasmablastic 
phenotype upon long‑term co‑culture on osteoclasts [83]. 
More recently, Karadimitris and colleagues reported 
epigenetic plasticity in MM patient samples and xenograft 
assays, where clinical drug resistance was attributed 
to bidirectional transitions between MM plasma cells 
and more quiescent pre‑plasma cells [84]. Our results 
also complement the recent findings of Tiedemann and 
colleagues implicating less mature pre‑plasma cells 
as contributing to therapeutic proteasome inhibitor 
resistance in MM [7]. Considered from this perspective, 
it is notable in view of its activity as a reprogramming 
factor that KLF4 target genes in embryonic stem cells 
were enriched in the differentially expressed genes in 
KMS‑11/Cfz and KMS‑34/Cfz cells [28]. These results 
suggest potential parallels with putative cancer stem‑like 
cells [13, 85]. In line with this notion, it has been reported 
that overexpression of KLF4 in breast cancer cells led to 
an increase of the cancer stem cell‑like population [86]. 
In that work, KLF4‑mediated maintenance of stem cell‑
like characteristics was accompanied by increased cell 
migration and invasion of the malignant cells. Our future 
studies will further examine the mechanistic ramifications 
of KLF4 expression as regards relapse and treatment 
resistance in MM, and the utility of the KMS‑11/Cfz and 
KMS‑34/Cfz MM models for the development of novel 
autophagy‑targeting combination therapies. 
MATERIALS AND METHODS
Cell lines, plasmids and transfections
KMS‑11 and KMS‑34 MM cells were a kind gift 
from Dr. P. Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) 
[87]. Cells were cultured in RPMI 1640 with GlutaMAX 
(Life Technologies) supplemented with 10% fetal bovine 
serum (Cambrex BioScience), 100 U/ml penicillin and 
100 μg/ml streptomycin. The KLF4 expression vector 
containing a KLF4 cDNA (Accession No. BC030811.1) 
under the control of a cytomegalovirus promoter in 
the pReceiver‑M11 backbone was from GeneCopoeia 
(Cat. No. EX‑Z0482‑M11). The pBABEpuro GFP‑LC3 
autophagy reporter plasmid was from Addgene (Plasmid 
No. 22405) [86]. Transfections were performed using the 
Amaxa nucleofector system with solution V and program 
X‑001 settings (Lonza). Transfected cell lines were 
selected in 0.5 mg/ml G418 (pReceiver‑M11 KLF4) or 
0.5 μg/ml puromycin (pBABEpuro GFP-LC3). GFP-LC3-
expressing cells were sorted on a FACSAria instrument 
equipped with FACSDiva software (BD Biosciences).
Antibodies and reagents
The following antibodies were used: anti‑KLF4 
(D1F2) rabbit mAb (Cell Signaling Technology, Cat. 
No. 12173); anti-α-tubulin mouse mAb (DM1A) (EMD 
Millipore Corporation, Cat. No. CP06); anti‑p62/SQSTM1 
(Clone 3) mouse mAb (BD Transduction Laboratories, 
Cat. No. 610832); anti-LC3B affinity isolated rabbit 
polyclonal antibody (Sigma‑Aldrich, Cat. No. L7543); and 
anti‑eIF4E (P‑2) mouse mAb (Santa Cruz Biotechnology, 
Cat. No. sc-9976). Carfilzomib was obtained from Active 
Biochem (Cat. No. A‑1098), chloroquine was purchased 
from Selleck Chemicals (Cat. No. S4157), and the 
lysosomal inhibitors E‑64d (Cat. No. E8640), leupeptin 
(Cat. No. 103476‑89‑7) and pepstatin A (Cat. No. 77170) 
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were from Sigma‑Aldrich.
Microarray gene expression analysis and 
quantitative real-time qRT-PCR validation
Total RNA was isolated with the miRNeasy mini kit 
(Qiagen, Cat. No. 217004). Microarray gene expression 
analysis of triplicate samples was carried out by 
Expression Analysis, Inc. (Durham, NC) using Affymetrix 
GeneChip Human Genome U133 Plus 2.0 arrays. The data 
have been deposited in GEO (http://www.ncbi.nlm.nih.
gov/geo/) under accession number GSE69078. Reverse 
transcription was performed with the SuperScript VILO 
cDNA synthesis kit (Life Technologies, Catalog No. 
11754‑250). Real‑time qRT‑PCR was performed using 
the Power SYBR Green reagent (Life Technologies, Cat 
No. 4368708) on an ABI Prism 7000 Sequence Detection 
System (Life Technologies) as previously described [13]. 
Primers synthesized by Sigma‑Aldrich included: CCND1, 
forward, GCTCACGCTTACCTCAACCA, reverse, 
GACAGACAAAGCGTCCCTCA; CYP1A1, 
forward, GCTGCCTTCTGGCCTTGTAA, reverse, 
TGCCTGGATATGTGCACTCC; GLIPR1, 
forward, GACTGCGTTCGAATCCATAACA, 
reverse, GCTGGGTCCCAAGTCATGTA; HGF, 
forward, GACGCAGCTACAAGGGAACA, 
reverse, GGCAAAAAGCTGTGTTCGTG; 
HOXB7, forward, TGCAGTTTTGTAAGCCCTCT, 
reverse, GCAACCACAGGGTTAGTCCA; ID1, 
forward, CCAGCACGTCATCGACTACA, 
reverse, GGGGGTTCCAACTTCGGATT; IFIT3, 
forward, CTGGGTGGAAACCTCTTCAGC, 
reverse, GACCTCACTCATGATGGCTGTTTC; 
IGF1, forward, TGCAGGAGGGACTCTGAAAC, 
reverse, GCTGCGTGATATTTGAAAGGT; KLF4, 
forward, TCCATTACCAAGAGCTCATGCC, 
reverse, CGCGTAATCACAAGTGTGGG; MAPT, 
forward, AGCTTGTAGCTGCCAACCTC, 
reverse, TTTCCAAGGGGGTGTGTTCC; NQO1, 
forward, TAGCATTGGGCACACTCCAG, 
reverse, CCAGGCGTTTCTTCCATCCT; P4HA2, 
forward, GACACTTCCCTCTGTGACCA, 
reverse, TCATGTGCCCAATAGAGGTG; PSMB5, 
forward, CAGTACAAAGGCATGGGGCT, reverse, 
TCAGACACAGGGCCTCTCTTA; SLAMF7, 
forward, AGTCTGGCACGTAAGATGAACA, 
reverse, TCAAAAGCAGCCATTCCCCT; SQSTM1, 
forward, CTCCGCGTTCGCTACAAAAG, reverse, 
CAGAAGGTAGGCCTTCACGG; and TLR4, 
forward, TGCCGTTTTATCACGGAGGT, reverse, 
GGGAGGTTGTCGGGGATTTT.
Chromatin immunoprecipitation (ChIP)
ChIP was performed on the SQSTM1 promoter 
regions with 20 µg total chromatin and 5 µg of anti‑KLF4 
(D1F2) rabbit mAb using the SimpleChIP Enzymatic 
Chromatin IP Kit (Magnetic Beads) (Cell Signaling, 
Cat. No. 9003), and 4% of the precipitated material 
was used per qPCR reaction. GATA6 was included as 
a non‑target promoter. Background ChIP levels were 
obtained using 5 µg of normal rabbit IgG (Cat. No. 
2729). Primers used were: SQSTM1 promoter region 
1, forward, AGCTTTGTGCCCTGTACTCA, reverse, 
TGCAGTGAGCCTGATACCTG; SQSTM1 promoter 
region 2, ACCTCTGTGACCTTGGGTCT, reverse, 
GCTGTCCCGACGCTGAG; GATA6 promoter region 
1, forward, TGTTGAACTGTGCAGCTTTTCT, reverse, 
TAATGATGCACACACAACCTGA; GATA6 promoter 
region 2, forward, ATTCCCAGCAGGCTTATTGTAAA, 
reverse, CAGAAGCAGACAACCACGATAG.
Confocal microscopy
Cells (2.5 x 105) were centrifuged onto a microscope 
slide at 1,000 rpm for 5 minutes using a Shandon Cytospin 
4 instrument. The cells were then immediately fixed in 
3.7% formaldehyde for 5 minutes at room temperature 
and permeabilized with 0.5% Triton X‑100 in phosphate‑
buffered saline (PBS) for 15 minutes at room temperature. 
Following permeabilization, the cells were rinsed with 
PBS and blocked in PBS containing 10% goat serum and 
0.01% Triton X‑100 for 1 hour at room temperature. The 
cells were then incubated with anti‑KLF4 and anti‑eIF4E 
antibodies diluted to final concentrations of 0.4 µg/ml, 
in PBS containing 1% goat and 0.01% Triton X‑100 for 
1 hour at room temperature. The cells were rinsed with 
PBS and then incubated with Alexa Fluor 568‑conjugated 
goat anti‑rabbit and Alexa Fluor 488‑conjugated goat anti‑
mouse secondary antibodies (Life Technologies) diluted 
1:500 in PBS containing 1% goat serum and 0.01% 
Triton X‑100 for 1 hour at room temperature. The cells 
were rinsed with PBS and mounted with Fluoromount 
G (Electron Microscopy Sciences). Cells expressing 
the GFP-LC3 reporter were fixed in 1% methanol free 
paraformaldehyde (Electron Microscopy Sciences) in 
PBS overnight at 4oC then centrifuged onto a microscope 
slide and mounted with Fluoromount G. Imaging analysis 
was performed on a Cell Observer SD spinning disk 
confocal system equipped with Zen software (Carl Zeiss 
Microscopy).
Cytotoxicity assay
Cells were treated with carfilzomib and chloroquine 
at the indicated concentrations and cell growth was 
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measured using the alamarBlue cell viability and 
proliferation reagent (Life Technologies) as previously 
described [13].
Autophagy detection
Autophagy was measured with the Cyto‑
ID autophagy detection kit (Enzo, Cat. No. ENZ‑
51031‑K200) using a FACSAria instrument, and data were 
analyzed with FlowJo Mac v10.0.2 (Tree Star). Autophagy 
activity factor (AAF) values were calculated using the 
following equation: AAF = 100 × (MFI 
carfilzomib-resistant
 − 
MFI parental) / MFI carfilzomib resistant. MFI is mean fluorescence 
intensity, and AAF expresses the level of autophagy in 
live cells as the difference between the amount of Cyto‑ID 
Green autophagy dye within cells [46]. GFP‑LC3 puncta 
were detected by confocal microscopy as described above.
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